Menopause Biomarker Tracking Guide
Which hormones, metabolic markers, and bone density indicators to test — and when. Includes how each test is read against guideline and reference ranges, and how to interpret trends over time.
- Lab reference ranges describe typical results; during perimenopause, symptoms and trends over time often say more than a single value
- Single-point hormone tests during perimenopause can be misleading; trend over time is more valuable than any one number
- The most important metabolic markers to track shift during menopause: lipids, insulin sensitivity, and inflammatory markers all change
- Bone-density screening is recommended for women 65 and older and for younger postmenopausal women at increased risk
- Most women need a few well-chosen tests, repeated as their doctor advises, rather than frequent hormone panels
The Testing Philosophy: Trends Over Snapshots
The menopausal transition makes single-point lab testing unreliable. The transition is marked by wide hormonal fluctuations and irregular cycles,1 so estradiol and FSH can look very different from one month to the next. Progesterone depends entirely on whether ovulation occurred that cycle. This volatility doesn't mean testing is useless — it means you need to track trends over time rather than react to any single result.
The goal is to build a biomarker trajectory that shows you: where you are in the transition, how your metabolic health is shifting, whether interventions (exercise, nutrition, HRT) are working, and where emerging risks are developing before they become clinical problems.
Tier 1: Reproductive Hormones
These markers confirm menopausal staging and guide HRT decisions.
| Marker | How it's read | Notes |
|---|---|---|
| FSH | Varies by cycle phase and lab | Rises as ovarian function declines; single values fluctuate widely during perimenopause, so trends and symptoms say more than one result. |
| Estradiol (E2) | Varies by cycle phase and lab | Highly variable during perimenopause and low after menopause. Hormone therapy is judged on symptoms and risks, not on reaching a blood level. |
| Progesterone | Varies by cycle phase and lab | Only interpretable when matched to the phase of the cycle. |
| AMH | Age-specific; declines with age | Reflects remaining ovarian reserve. |
| Total testosterone | Varies by lab; ranges for women differ from men | Interpret with your clinician; testosterone ranges for men do not apply. |
| SHBG | Varies by sex and age | Binds testosterone and estradiol; oral estrogen raises it. |
| DHEA-S | Age- and sex-specific ranges | Declines with age; in a trial in older adults, supplements did not improve fitness, strength or insulin sensitivity. |
During perimenopause, draw FSH and estradiol on cycle day 2–5 (early follicular phase) for the most interpretable results. If cycles are too irregular to time, draw on any day but note where you are in the cycle. For progesterone, draw on day 21 (or 7 days after expected ovulation). Post-menopause: timing doesn't matter — draw anytime.
Tier 2: Metabolic Markers
The menopausal transition accelerates metabolic changes that drive cardiovascular and diabetes risk. These markers are often more important for long-term health outcomes than the reproductive hormones themselves.
| Marker | How it's read | Notes |
|---|---|---|
| Fasting insulin | No agreed cut-off | Rises with insulin resistance; most useful tracked over time alongside glucose. |
| HbA1c | Normal under 5.7% · prediabetes 5.7–6.4% · diabetes 6.5%+ | Average blood sugar over about three months. |
| Fasting glucose | Normal under 100 mg/dL · prediabetes 100–125 · diabetes 126+ | A result in the diabetes range needs confirming with a repeat test. |
| HOMA-IR | No universal cut-off | Calculated from fasting insulin and glucose; thresholds vary with age, sex and population. |
| ApoB | No single cut-off | Counts atherogenic particles; read it with your overall cardiovascular risk. |
| LDL cholesterol | Desirable under 100 mg/dL · very high 190+ | The main target of cholesterol treatment. |
| HDL cholesterol | Low under 50 mg/dL for women · 60+ best | Low HDL is linked to higher cardiovascular risk. |
| Triglycerides | Normal under 150 mg/dL · borderline 150–199 · high 200+ | Very high levels (500+) can cause pancreatitis. |
| Lp(a) | Under 30 mg/dL (75 nmol/L) rules out risk · over 50 mg/dL (125 nmol/L) rules it in | Largely inherited; measure once in adulthood. |
| hsCRP | Low risk under 1 mg/L · average 1–3 · high over 3 | Infections raise CRP, so repeat a high result when you are well. |
In the SWAN study, total cholesterol, LDL cholesterol and ApoB rose sharply in the year around the final menstrual period, a pattern that points to menopause itself rather than ageing alone.4 The American Heart Association describes the transition as a time of accelerating cardiovascular risk and stresses monitoring women’s health in midlife.2 Recheck your lipids as your doctor advises. Our Lab Results Interpreter can help you understand your numbers.
Tier 3: Bone, Thyroid, and Micronutrient Markers
| Marker | How it's read | Notes |
|---|---|---|
| DEXA scan (T-score) | Read against the WHO categories on your report | The US Preventive Services Task Force recommends screening women 65 and older, and younger postmenopausal women at increased risk. |
| Vitamin D (25-OH) | Adequate 20–50 ng/mL · deficient under 12 · above 50 not advised (NIH) | The Endocrine Society's 2024 guideline suggests against routine testing without an established reason and found no clear evidence for any target level. |
| Calcium (serum) | Reference range varies by lab | Tightly regulated, so rarely abnormal; it does not reflect calcium intake or bone health. |
| TSH | Usual range about 0.4–4.8 mIU/L (labs vary) | Thyroid problems become more common with age and can mimic menopause symptoms. |
| Free T4 | Reference range varies by lab | Checked when TSH is abnormal. |
| Free T3 | Reference range varies by lab | Usually interpreted alongside TSH and free T4. |
| Ferritin | Iron deficiency below 15 ng/mL (below 70 with inflammation); above 150 may signal iron overload risk (WHO) | May rise after periods stop. Inflammation also raises ferritin. |
| Magnesium (serum) | Normal 1.7–2.2 mg/dL (labs vary slightly) | Only a small share of body magnesium is in the blood, so a normal level does not rule out low stores. |
| Vitamin B12 | Subnormal below 200–250 pg/mL | With symptoms and a level of 150–399 pg/mL, a methylmalonic acid test can confirm deficiency. |
The Menopause Testing Schedule
Early Perimenopause (Cycles Changing, Age ~40–45)
Get a standard check-up and a few useful baselines; hormone tests are rarely needed to confirm perimenopause.
- Hormones: only if the picture is unclear or symptoms suggest a specific problem
- Metabolic: HbA1c or fasting glucose, lipids (ApoB optional), Lp(a) once
- Thyroid: TSH if you have symptoms
- Micronutrients: only if you are at risk of a deficiency
- DEXA scan: if your risk factors call for one
Late Perimenopause (Irregular Cycles, Symptoms, Age ~45–51)
This is the period of most rapid change, but more frequent hormone tests rarely change decisions.
- Hormones: not needed routinely
- Lipids and blood sugar: as your doctor advises
- If starting hormone therapy: follow-up is based on symptoms and side effects, not blood levels
- DEXA scan: per your risk factors
Post-Menopause (Stable, 1+ Year Since Last Period)
Annual testing is typically sufficient once hormones and metabolic markers stabilize.
- Routine check-ups: blood pressure, cholesterol and blood sugar
- If on hormone therapy: an annual review of benefits and risks with your clinician
- DEXA scan: screening for all women from 65; repeat timing depends on your result
- Cardiovascular: cholesterol as advised; a calcium score can help if your doctor is unsure about a statin
Use our Blood Panel Builder to create a custom testing plan with Quest/LabCorp codes. Then use the Lab Results Interpreter to see how your results compare with guideline categories.
How to Read Trends: What Changes Mean
Rising FSH + Falling AMH = Transition is progressing
This is expected and not alarming. It confirms you're moving through the transition.
Rising Fasting Insulin or HOMA-IR = Metabolic warning
This is actionable. A rising trend in your own results suggests worsening insulin resistance. Resistance training, more fiber and fewer refined carbohydrates help; check HbA1c, the standard test, as your doctor advises.
Rising ApoB or LDL = Cardiovascular risk acceleration
Expected during the transition but still requires attention. Discuss treatment with your doctor, who will weigh it against your overall cardiovascular risk.
Declining DEXA T-score = Bone loss is occurring
Bone loss is fastest from about a year before to two years after the final menstrual period;3 in SWAN, spine density fell 5.6% over four years in women who became naturally postmenopausal.5 Get enough calcium and vitamin D (20 ng/mL or more is sufficient for most people) and do resistance and impact exercise. A T-score of −2.5 or lower means osteoporosis, and your doctor may suggest treatment at higher scores based on your overall fracture risk. See our Bone Density Optimization Protocol.
Rising hs-CRP = Inflammation increasing
Common during menopause as visceral fat increases. Exercise, weight management and a Mediterranean-style diet help. A result above 3 mg/L, repeated when you are well, is considered high risk.
References & Sources
- 1Santoro N, et al. "The Menopause Transition: Signs, Symptoms, and Management Options." J Clin Endocrinol Metab. 2021;106(1):1-15. PubMed · DOI
- 2El Khoudary SR, et al. "Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association." Circulation. 2020;142(25):e506-e532. PubMed · DOI
- 3Greendale GA, et al. "Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women's Health Across the Nation (SWAN)." J Bone Miner Res. 2012;27(1):111-8. PubMed · DOI
- 4Matthews KA, et al. "Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition?" J Am Coll Cardiol. 2009;54(25):2366-73. PubMed · DOI
- 5Sowers MR, et al. "Hormone predictors of bone mineral density changes during the menopausal transition." J Clin Endocrinol Metab. 2006;91(4):1261-7. PubMed · DOI
Ready to build your testing plan?
Use our Blood Panel Builder to select the right tests with Quest and LabCorp codes.
Build Your Panel →